Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2016 - 2026)

Ironwood Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 161.38% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 19616.0% to 161.38% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.97%, a 2153.0% decrease, with the full-year FY2025 number at 4.97%, down 2153.0% from a year prior.
  • EBITDA Margin hit 161.38% in Q4 2025 for Ironwood Pharmaceuticals, down from 61.84% in the prior quarter.
  • Over the last five years, EBITDA Margin for IRWD hit a ceiling of 666.87% in Q4 2023 and a floor of 989.17% in Q2 2023.
  • Historically, EBITDA Margin has averaged 21.19% across 5 years, with a median of 38.96% in 2022.
  • Biggest five-year swings in EBITDA Margin: crashed -102730bps in 2023 and later soared 101563bps in 2024.
  • Tracing IRWD's EBITDA Margin over 5 years: stood at 35.32% in 2021, then increased by 29bps to 45.59% in 2022, then soared by 1363bps to 666.87% in 2023, then plummeted by -95bps to 34.78% in 2024, then tumbled by -564bps to 161.38% in 2025.
  • Business Quant data shows EBITDA Margin for IRWD at 161.38% in Q4 2025, 61.84% in Q3 2025, and 53.17% in Q2 2025.